A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection.

Autor:	Counoupas C; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia.; Tuberculosis Research Program at the Centenary Institute, The University of Sydney, Sydney, NSW, Australia., Johansen MD; Centre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney, NSW, Australia., Stella AO; Kirby Institute, University of New South Wales, Sydney, NSW, Australia., Nguyen DH; Centre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney, NSW, Australia., Ferguson AL; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia.; Tuberculosis Research Program at the Centenary Institute, The University of Sydney, Sydney, NSW, Australia., Aggarwal A; Kirby Institute, University of New South Wales, Sydney, NSW, Australia., Bhattacharyya ND; Tuberculosis Research Program at the Centenary Institute, The University of Sydney, Sydney, NSW, Australia., Grey A; Department of Clinical Immunology, Royal Prince Alfred Hospital, Sydney, NSW, Australia., Hutchings O; RPA Virtual Hospital, Sydney Local Health District, Sydney, NSW, Australia., Patel K; School of Life and Environmental Sciences, The University of Sydney, Sydney, NSW, 2006, Australia., Siddiquee R; School of Life and Environmental Sciences, The University of Sydney, Sydney, NSW, 2006, Australia., Stewart EL; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia., Feng CG; Tuberculosis Research Program at the Centenary Institute, The University of Sydney, Sydney, NSW, Australia., Hansbro NG; Centre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney, NSW, Australia., Palendira U; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia., Steain MC; Tuberculosis Research Program at the Centenary Institute, The University of Sydney, Sydney, NSW, Australia., Saunders BM; Centre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney, NSW, Australia., Low JKK; School of Life and Environmental Sciences, The University of Sydney, Sydney, NSW, 2006, Australia., Mackay JP; School of Life and Environmental Sciences, The University of Sydney, Sydney, NSW, 2006, Australia., Kelleher AD; Kirby Institute, University of New South Wales, Sydney, NSW, Australia., Britton WJ; Tuberculosis Research Program at the Centenary Institute, The University of Sydney, Sydney, NSW, Australia.; Department of Clinical Immunology, Royal Prince Alfred Hospital, Sydney, NSW, Australia., Turville SG; Kirby Institute, University of New South Wales, Sydney, NSW, Australia., Hansbro PM; Centre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney, NSW, Australia. Philip.Hansbro@uts.edu.au., Triccas JA; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia. jamie.triccas@sydney.edu.au.; Sydney Institute for Infectious Diseases and Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia. jamie.triccas@sydney.edu.au.
Jazyk:	angličtina
Zdroj:	NPJ vaccines [NPJ Vaccines] 2021 Nov 30; Vol. 6 (1), pp. 143. Date of Electronic Publication: 2021 Nov 30.
DOI:	10.1038/s41541-021-00406-4
Abstrakt:	Global control of COVID-19 requires broadly accessible vaccines that are effective against SARS-CoV-2 variants. In this report, we exploit the immunostimulatory properties of bacille Calmette-Guérin (BCG), the existing tuberculosis vaccine, to deliver a vaccination regimen with potent SARS-CoV-2-specific protective immunity. Combination of BCG with a stabilised, trimeric form of SARS-CoV-2 spike antigen promoted rapid development of virus-specific IgG antibodies in the blood of vaccinated mice, that was further augmented by the addition of alum. This vaccine formulation, BCG:CoVac, induced high-titre SARS-CoV-2 neutralising antibodies (NAbs) and Th1-biased cytokine release by vaccine-specific T cells, which correlated with the early emergence of T follicular helper cells in local lymph nodes and heightened levels of antigen-specific plasma B cells after vaccination. Vaccination of K18-hACE2 mice with a single dose of BCG:CoVac almost completely abrogated disease after SARS-CoV-2 challenge, with minimal inflammation and no detectable virus in the lungs of infected animals. Boosting BCG:CoVac-primed mice with a heterologous vaccine further increased SARS-CoV-2-specific antibody responses, which effectively neutralised B.1.1.7 and B.1.351 SARS-CoV-2 variants of concern. These findings demonstrate the potential for BCG-based vaccination to protect against major SARS-CoV-2 variants circulating globally. (© 2021. The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu